ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Innovating shorter, all-oral, precise, individualized treatment regimen for rifampicin-resistant tuberculosis (INSPIRE TB): study protocol for a pragmatic randomised controlled trial.BMC infectious diseases · 2026Trial
- Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women.Antimicrobial agents and chemotherapy · 2026Article
- Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Navigating Tuberculosis in Pregnancy and Lactation: A Review of Maternal and Neonatal Considerations.Diseases (Basel, Switzerland) · 2026Review
- Successful treatment of pre-extensively drug-resistant tuberculous meningoencephalomyelitis in pregnancy with a bedaquiline and delamanid-based regimen: a case report.BMC infectious diseases · 2026Article
- Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s.The Journal of infectious diseases · 2026Observational
- Clinical characteristics of pregnant patients with rifampicin-resistant tuberculosis: a retrospective analysis.BMC infectious diseases · 2026Article
- Expanding treatment options for syphilis during pregnancy: a review of alternatives to penicillin.Frontiers in global women's health · 2026Review
- An Update on the Clinical Management of HIV and Tuberculosis Co-Infection in Pregnancy: TB Preventative Therapy, Long-Acting ARVs, and Bedaquiline-Based Regimens.Current HIV/AIDS reports · 2025Review
- Tuberculosis disease among people with HIV: therapeutic advances.The lancet. HIV · 2025Review
- Update in tuberculosis treatment: a scoping review of current practices.Breathe (Sheffield, England) · 2025Review
- Adverse pregnancy outcomes and complications of tuberculosis in pregnant women.Frontiers in cellular and infection microbiology · 2025Review
- Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
Corrections and comments
- Commented on by
Authors and funding
28 authors at 10 institutions in 6 countries.
Funding
Abstract
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.